Close
(0) items
You have no items in your shopping cart.
All Categories
    Filters
    Preferences
    Search

    Sick Money: Sky-high Prices and Dirty Tricks: Inside the Global Pharmaceutical Industry

    €13.75
    A Compelling Expose of Sky-high Prices and Dirty Tricks Inside the Global Pharmaceutical Industry
    ISBN: 9781838850296
    AuthorKenber, Billy
    Pub Date07/07/2022
    BindingPaperback
    Pages432
    AvailabilityCurrently out of stock. If available, delivery is usually 5-10 working days.
    EditionMain
    Availability: Out of Stock

    THE PHARMACEUTICAL INDUSTRY IS BROKEN

    From the American hedge fund manager who drastically hiked the price of an AIDS pill to the children's cancer drugs left intentionally to expire in a Spanish warehouse, the signs of this dysfunction are all around. A system built to drive innovation and improve patient care has been distorted to maximise profits.

    In Sick Money, the investigative journalist who exposed a billion-pound British price-hiking scandal goes inside the global battle over high drug prices. From secret deals to patients forced to turn to the black market, Billy Kenber reveals how medicines have become nothing more than financial assets. He offers a diagnosis of an industry in crisis - and a prescription for how it could be fixed.

    Write your own review
    • Only registered users can write reviews
    *
    *
    • Bad
    • Excellent
    *
    *
    *

    THE PHARMACEUTICAL INDUSTRY IS BROKEN

    From the American hedge fund manager who drastically hiked the price of an AIDS pill to the children's cancer drugs left intentionally to expire in a Spanish warehouse, the signs of this dysfunction are all around. A system built to drive innovation and improve patient care has been distorted to maximise profits.

    In Sick Money, the investigative journalist who exposed a billion-pound British price-hiking scandal goes inside the global battle over high drug prices. From secret deals to patients forced to turn to the black market, Billy Kenber reveals how medicines have become nothing more than financial assets. He offers a diagnosis of an industry in crisis - and a prescription for how it could be fixed.